Navigation Links
Uroplasty to Present at ROTH Capital Partners 23rd Annual OC Growth Stock Conference
Date:3/7/2011

MINNEAPOLIS, March 7, 2011 /PRNewswire/ -- Uroplasty, Inc. (Nasdaq: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, announced today that it will be presenting at the ROTH Capital Partners 23rd Annual OC Growth Stock Conference on Monday, March 14, 2011 at 8:30 am Pacific Time at the Ritz-Carlton Laguna Nigel. David Kaysen, Uroplasty's President and CEO, and Medi Jiwani, Uroplasty's Vice President and CFO, will discuss the Company's business strategy and historic financial results.

Attendance at the conference is by invitation only. A live audio webcast of the presentation will be broadcast via the Internet.  Those interested in listening to the webcast may access it at http://www.wsw.com/webcast/roth24/upi/ or through Uroplasty's website at www.uroplasty.com. An archived replay of the presentation will be available for 90 days.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent PC Neuromodulation System, the only FDA-cleared system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

For Further Information:

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, Treasurer

952.426.6140

EVC Group

Doug Sherk/Jenifer Kirtland (Investors), 415.896.6820

Chris Gale (Media), 646.201.5431




'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplasty Reports Financial Results for the Third Quarter FY2011
2. Uroplasty to Issue Third Quarter 2011 Results on January 27, 2011
3. Uroplasty Announces Addition of Robert Kill to its Board of Directors
4. Additional Regional Medicare Carrier Initiates Coverage for Posterior Tibial Nerve Stimulation (PTNS) Delivered via Uroplastys Urgent® PC Neuromodulation System
5. Uroplasty Inc. Announces CPT® Category I Code and Associated Reimbursement Value for Posterior Tibial Nerve Stimulation
6. Uroplasty Reports Financial Results for the Second Quarter FY2011
7. Uroplasty to Issue Second Quarter 2011 Results on October 27, 2010
8. Uroplasty to Present at The 5th Annual JMP Securities Healthcare Conference
9. Coverage Initiated by Two Regional Medicare Carriers for Posterior Tibial Nerve Stimulation (PTNS) Delivered Via Uroplastys Urgent® PC Neuromodulation System
10. Uroplasty to Present at Global Hunter Securities Inaugural Healthcare Conference
11. Uroplasty Reports Results for Second Quarter FY2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... , July 12, 2017  Eli Lilly and Company (NYSE: ... with generic companies to resolve pending patent litigation in the ... Virginia regarding the Cialis ® (tadalafil) unit ... April 26, 2020. As part of the agreement, Cialis exclusivity ... 27, 2018. "The unit dose patent for Cialis ...
(Date:7/11/2017)... Md. , July 11, 2017  The global ... estimated revenues of approximately $394.1 million in 2016.  Although ... trend of solid growth, in particular as a result ... clinical practice, and the recent introduction of a significant ... need for less-invasive testing of tumor biomarkers to guide ...
(Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( ... development of oral drug delivery systems, announced today that ... to schedule an End-of-Phase II meeting with Oramed for ... insulin capsule ORMD-0801 in the treatment of type 2 ... endpoints by indicating a statistically significant lowering of glucose ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... Axiad IDS , a leading provider of ... with WALLIX to expand its solution to help government contractors more quickly ... number of ways to address the authentication requirements within NIST SP800-171, but no ...
(Date:7/24/2017)... ... 24, 2017 , ... Anyone who uses scales know they have limits; a ... using that same scale to dispense medication. The first example is an issue of ... why it is important to have the right balance for the process. METTLER TOLEDO’s ...
(Date:7/24/2017)... ... ... A Southern California-based author has released a new book which details her ... them. “Forbidden Memories: A Memoir,” by author Michelle V. Madsen, highlights the author’s journey ... In “Memories,” readers get a firsthand look at what Michelle has been through in ...
(Date:7/24/2017)... VA (PRWEB) , ... July 24, 2017 , ... ... out how to change manufacturers future. , The agency is hammering out a ... Act, one of the farthest-ranging laws ever to affect FDA-regulated firms. The new ...
(Date:7/24/2017)... ... July 24, 2017 , ... “A Short Walk to the Mailbox”: a remarkable ... creation of published author, Ed Clark. Ed Clark is a church music director ... as a minister of music and worship leader for over fifty years. He ...
Breaking Medicine News(10 mins):